Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
465
Employees465
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
465
Employees465

REPL Key Statistics

Market cap
1.26B
Market cap1.26B
Price-Earnings ratio
-4.27
Price-Earnings ratio-4.27
Dividend yield
Dividend yield
Average volume
6.44M
Average volume6.44M
High today
$15.39
High today$15.39
Low today
$14.70
Low today$14.70
Open price
$15.21
Open price$15.21
Volume
2.40M
Volume2.40M
52 Week high
$15.71
52 Week high$15.71
52 Week low
$1.50
52 Week low$1.50

Stock Snapshot

With a market cap of 1.26B, Replimune(REPL) trades at $14.70. The stock has a price-to-earnings ratio of -4.27.

During the trading session on 2026-08-15, Replimune(REPL) shares reached a daily high of $15.39 and a low of $14.70. At a current price of $14.70, the stock is 0.0% higher than the low and still -4.5% under the high.

Trading volume for Replimune(REPL) stock has reached 2.4M, versus its average volume of 6.44M.

Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $15.71 and a low of $1.50.

Over the past 52 weeks, Replimune(REPL) stock has traded between a high of $15.71 and a low of $1.50.

REPL News

TipRanks 15h
Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop

Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that the company misled investors about the regulatory strength of its RP1...

Investing.com 19h
Replimune Group stock may move 5.6% on earnings release - Investing.com

...

Replimune Group stock may move 5.6% on earnings release - Investing.com
Simply Wall St 2d
Replimune Group Stock Looks Pricey On Book Value Despite 199% Returns

Replimune Group stock has delivered a very strong 199.4% return over the past year, yet the broader valuation checks still flag the shares as leaning expensive...

Replimune Group Stock Looks Pricey On Book Value Despite 199% Returns

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

More REPL News

TipRanks 2d
Replimune’s Top Brass Quietly Unload a Wave of Shares in Coordinated Moves

New insider activity at Replimune Group ( (REPL) ) has taken place on August 12, 2026. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Prem...

Simply Wall St 5d
How Investors Are Reacting To Replimune Group FDA Accelerated Approval For New Melanoma Therapy

Earlier this month, Replimune Group announced that the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolu...

How Investors Are Reacting To Replimune Group FDA Accelerated Approval For New Melanoma Therapy
TipRanks 5d
Replimune Raises $150 Million in Equity Offering

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Simply Wall St 6d
Replimune Group Wins FDA Approval, Is The Valuation Still Too Rich?

Replimune Group (REPL) stock is back in focus after Robbins LLP announced a securities class action tied to the company’s RP1 melanoma program and the U.S. Food...

Replimune Group Wins FDA Approval, Is The Valuation Still Too Rich?

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.